Chimeric antigen receptors (CARs) comprise interact domains, of which target cancer cell expressed antigens and allow T cell to efficiently kill the cancer cell. FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas.